AIM ImmunoTech Inc. has fully satisfied a promissory note held by Streeterville Capital, LLC by converting the outstanding debt into common stock. The company entered into a series of exchange agreements between August 31 and September 3, 2026, effectively eliminating all remaining obligations under the note.
Key Details
- Transaction Value: Approximately $1,224,341 of debt was converted into 5,065,840 shares of common stock.
- Conversion Price: The exchange was executed at an average conversion price of approximately $0.24 per share.
- Outcome: As of September 3, 2026, the promissory note, originally dated February 16, 2024, is considered satisfied in full with no amounts remaining owed.